Loading clinical trials...
Loading clinical trials...
An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer
Conditions
Interventions
Apatinib
Nivolumab
Locations
1
United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
Start Date
December 22, 2017
Primary Completion Date
October 28, 2020
Completion Date
March 16, 2022
Last Updated
April 7, 2023
NCT06066138
NCT06498635
NCT05673200
NCT03375307
NCT04235764
NCT06842498
Lead Sponsor
Elevar Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions